腺性膀胱炎三种治疗方法治疗效果的随访观察

目的　比较腺性膀胱炎三种治疗方法的效果。方法　 86例腺性膀胱炎患者分别行膀胱药物灌注、经尿道电切、经尿道电切加膀胱药物灌注治疗。随访观察症状缓解程度和膀胱镜病检结果 1年。结果　 73例完成了随访调查 ,占 84.9%。三种方法治疗后症状缓解程度 ,差异无显著性意义 (P >0 .0 5 ) ;膀胱镜病检复查 ,灌注治疗效果好于电切治疗效果 ,综合治疗效果好于电切治疗效果 ,差异具有显著性意义 ;比较灌注治疗后膀胱镜病检阴性例数 ( 2 2 /2 8)与综合治疗后膀胱镜病检阴性例数 ( 3 0 /3 4) ,差异无显著性意义 ( χ2 =1.0 60 ,P =0 .3 0 3 )。结论　膀胱药物灌注和经尿道电切加膀胱药物灌注的膀胱镜病检复查 ,效果好于电切治疗的效果。     

Intravenous drug abuse and Type 1 diabetes: financial and healthcare implications.

AIMS: To determine the morbidity, mortality and healthcare costs of intravenous drug-abusing patients with Type 1 diabetes (IVDA-DM), who are admitted to hospital. METHODS: Retrospective case note analysis of admissions, complications and cost estimation over a 6-year period. Each drug-abusing patient (IVDA-DM) (n = 9) was compared with two controls (n = 18) with Type 1 diabetes but without a history of intravenous drug abuse (DM-controls). Admissions were also analysed for patients with intravenous drug abuse, but without Type 1 diabetes (IVDA-controls) (n = 198). Admissions were at a University teaching hospital in Liverpool, UK. DM-controls were drawn from a population attending diabetes outpatient clinics between 1997 and 2002 at the same hospital. The main outcome measures were: the duration and healthcare costs of hospital admissions per year, outpatient attendances per year, glycated haemoglobin (HbA(1c)), weight, micro- and macrovascular complications and mortality. RESULTS: Multiple admissions, mainly related to ketoacidosis, led to marked differences in mean (95% CI) inpatient days per year per patient [IVDA-DM 28.1 (13.6-42.7) vs. DM-control 1.1 (0.2-1.9); P < 0.0001], mean inpatient days per year per patient in critical care bed (IVDA-DM 1.7 (-0.7-4.2) vs. DM-control 0; P < 0.02) and mean costs of admission, per patient per year (pound sterling 7320 vs. pound sterling 230). The IVDA-DM group frequently omitted insulin, were underweight, failed to attend as outpatients and five had died by the end of 2002. The IVDA-controls spent considerably less time in hospital [3.4 (2.8-3.9) days per patient per year]. CONCLUSION: IVDA-DM patients have higher rates of diabetes complications, are admitted more frequently and have a high mortality compared with DM and IVDA-controls. The cost of inpatient care of this small group of patients was considerable.     

补肾抗衰口服液对大鼠衰老模型免疫器官影响的实验研究

研究补肾抗衰口服液对大鼠衰老模型免疫器官胸腺和脾脏的影响.结果显示,模型组大鼠胸腺和脾脏重量减轻,胸腺重/体重比值、脾重/体重比值减小,胸腺组织学观察,显示萎缩改变;药物组大鼠胸腺和脾脏重量、胸腺重/体重、脾重/体重比值接近正常对照组,胸腺组织学观察,未显示萎缩改变.本研究结果表明,补肾抗衰口服液能延缓胸腺和脾脏萎缩,保护机体的正常免疫功能,提示该药有抗衰老的作用.     

Cases of buprenorphine abuse in India.

Buprenorphine was introduced as a potent analgesic with low abuse potential. Reports of buprenorphine abuse by opiate abusers have accumulated over the years, highlighting its use as a cheap alternative to heroin. The lower potency compared with heroin is being compensated by using a cocktail of buprenorphine with benzodiazepines or cyclizine. This study of 18 cases seen over 3 years broadly confirms these findings. Four cases reported haematemesis during acute withdrawal, a symptom not reported in earlier studies.     

世界生物技术药品市场的现状及展望

生物技术的迅速发展将导致一场新的药物革命。预计2000年世界生物技术药品的销售额将达500亿美元。美国、日本和西方工业化国家的制药公司对生物技术药品的开发非常重视。目前,人生长激素、红细胞生长素和人胰岛素在医药市场中占有重要位置,毫无疑问,二十一世纪的医药市场将是生物技术药品的时代。     

肠溶阿斯匹林剂量和血阿斯匹林及水杨酸盐浓度与药效关系探讨

本文探讨了ＡＳＡ剂量与药效的关系及血ＡＳＡ、ＳＡ药物浓度监测的临床意义，结果表明：（１）ＡＳＡ剂量与６－ｋｅｔｏ－ＰＧＦ_（１α）抑制率呈正相关（Ｐ＜０．０１），而与ＴＸＢ_２及ＰＡｇＲ抑制率无相关性（Ｐ＞０．１）；（２）本文采用ＨＰＬＣ内标法同时测定血ＡＳＡ和ＳＡ浓度，结果准确，方法简便；（３）当口服小剂量ＡＳＡ防治ＣＩ时，监测血ＡＳＡ和ＳＡ以调整ＡＳＡ用药剂量的临床价值并非十分重要。     

垂体后叶素和硝酸甘油联合治疗食管静脉曲张破裂大出血

３０例肝硬化食管静脉曲张破裂大出血患者，用垂体后叶素０．２～０．４Ｕ／ｍｉｎ连续静脉滴注和硝酸甘油含服联合治疗。结果表明，近期止血有效申达８０％，死亡率１０％；无一例出现严重心绞痛和心电图异常。     

中药饮片加工炮炙在临床中的意义

本文简述了中药炮炙的根据、原理、方法以及各种不同辅料和炮炙方法对饮片药性与作用的影响。说明不同的炮炙方法可以直接影响和改变中药的药性和作用,影响到临床疗效,因此,必须重视中药饮片的炮炙工作。以确保临床安全有效的用药。